Table 1 Demographic and clinical characteristics of the study participants by diagnostic group.

From: Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases

Characteristic

Overall1

SCD1

MCI1

DEM1

p-value

N = 153

N = 13

N = 82

N = 58

Sex

    

0.172

Female

83 (54%)

9 (69%)

39 (48%)

35 (60%)

 

Male

70 (46%)

4 (31%)

43 (52%)

23 (40%)

 

Education (Y)

14.54 (± 3.19)

15.92 (± 3.17)

14.94 (± 3.10)

13.96 (± 3.16)

0.065

Age at PET (Y)

67.80 (± 9.63)

62.38 (± 8.69)†

71.43 (± 9.08)*†

67.58 (± 7.76)*

0.001

MMSE

24.98 (± 5.30)

29.08 (± 0.79)†,‡

25.43 (± 3.28)†,**

18.95 (± 5.41)‡,**

 < 0.001

Amyloid PET positive

80 (48%)

3 (23%)*,†

41 (50%)†

36 (62%)*

0.033

Centiloid

38.74 (± 45.61)

16.51 (± 31.65)

38.47 (± 45.90)

48.79 (± 47.08)

0.060

ε4 alle

    

0.479

Noncarrier

91 (60%)

8 (62%)

51 (62%)

32 (55%)

 

Heterozygot

51 (33%)

5 (38%)

27 (33%)

19 (33%)

 

Homozygot

11 (7%)

0 (0%)

4 (5%)

7 (12%)

 

Days between PET and LP

476.20 (± 504.63)

780.08 (± 513.87)*,†

415.62 (± 553.37)†

473.34 (± 427.76)*

 < 0.001

  1. Values are presented as mean (standard deviation) or counts (percentages), as appropriate. Group comparisons were conducted using ANOVA with subsequent Tukey HSD post hoc test or chi-square test. The threshold for amyloid positivity is > 20 CL.
  2. n (%); Mean (± SD)
  3. *p < 0.05, **p < 0.001, †p < 0.05, ‡p < 0.001
Back to article page